Events Calendar

Mon
Tue
Wed
Thu
Fri
Sat
Sun
M
T
W
T
F
S
S
26
27
28
29
30
31
2
3
4
5
6
7
8
9
10
8:30 AM - HIMSS Europe
11
12
13
14
15
16
17
18
19
20
21
22
26
27
28
29
1
2
3
4
5
6
e-Health 2025 Conference and Tradeshow
2025-06-01 - 2025-06-03    
10:00 am - 5:00 pm
The 2025 e-Health Conference provides an exciting opportunity to hear from your peers and engage with MEDITECH.
HIMSS Europe
2025-06-10 - 2025-06-12    
8:30 am - 5:00 pm
Transforming Healthcare in Paris From June 10-12, 2025, the HIMSS European Health Conference & Exhibition will convene in Paris to bring together Europe’s foremost health [...]
38th World Congress on  Pharmacology
2025-06-23 - 2025-06-24    
11:00 am - 4:00 pm
About the Conference Conference Series cordially invites participants from around the world to attend the 38th World Congress on Pharmacology, scheduled for June 23-24, 2025 [...]
2025 Clinical Informatics Symposium
2025-06-24 - 2025-06-25    
11:00 am - 4:00 pm
Virtual Event June 24th - 25th Explore the agenda for MEDITECH's 2025 Clinical Informatics Symposium. Embrace the future of healthcare at MEDITECH’s 2025 Clinical Informatics [...]
International Healthcare Medical Device Exhibition
2025-06-25 - 2025-06-27    
8:30 am - 5:00 pm
Japan Health will gather over 400 innovative healthcare companies from Japan and overseas, offering a unique opportunity to experience cutting-edge solutions and connect directly with [...]
Electronic Medical Records Boot Camp
2025-06-30 - 2025-07-01    
10:30 am - 5:30 pm
The Electronic Medical Records Boot Camp is a two-day intensive boot camp of seminars and hands-on analytical sessions to provide an overview of electronic health [...]
Events on 2025-06-01
Events on 2025-06-10
HIMSS Europe
10 Jun 25
France
Events on 2025-06-23
38th World Congress on  Pharmacology
23 Jun 25
Paris, France
Events on 2025-06-24
Events on 2025-06-25
International Healthcare Medical Device Exhibition
25 Jun 25
Suminoe-Ku, Osaka 559-0034
Events on 2025-06-30

Events

Latest News Press Releases

Peptide Therapeutics Market Structure and Its Segmentation for the Period 2026

peptide therapeutics

Peptide Therapeutics Market Structure and Its Segmentation for the Period 2026

Peptides are naturally happening biological molecules which play an essential role in significant biological activities. Many efforts have been taken in pharmaceutical research and development to evolve new peptides for the treatment of various chronic diseases. Around 7000 naturally active peptides have been discovered in the past few years, which act as hormones, neurotransmitters, ion channel ligands, and growth factors to provide various human physiologies. The growth of the Peptide Therapeutics market is directly related to increasing investments in drug discovery. R&D activities in peptide therapeutics are majorly focused on the evolution of drugs related to oncology and metabolic disorders, infectious diseases, and diabetes. A robust product pipeline in this field is also one of the factors projected to propel market growth soon. Besides the market growth drivers, the market restricting factors are the huge cost incurred in developing drugs and restricted regulatory requirements for drug approval. The Peptide Therapeutics Market is estimated to grow at the rate of 9.67% CAGR by 2026.

Peptide Therapeutics Market by Application

Metabolic
Cardiovascular Disorder
Respiratory
GIT
Anti-infection
Pain
Dermatology
CNS
Renal
Others

Peptide Therapeutics Market by Drug Type

Generic
Innovative

Peptide Therapeutics Market by Type of Manufacturing

In-house
Outsourced

Peptide Therapeutics Market by Synthesis Technology

Solid Phase Peptide Synthesis (SPPS)
Liquid Phase Peptide Synthesis (LPPS)
Hybrid Technology

Peptide Therapeutics Market by Geography

North America
Europe
Asia Pacific
Rest of the World

The cancer segment has held the maximum share in the peptide therapeutics market on the basis of application. Since there is an increasing number of cancer patients, it is eventually increasing the prescription of peptide therapeutics to treat cancer. Moreover, the rising demand for efficient and faster-acting therapeutics further accentuates the growth of the segment. As per the market by drug type, the innovative peptides segment has a significant share in the peptide therapeutics market. This is due to the high investments by various pharmaceuticals in research and development activities to develop and discover new drugs for the increasing number of chronic diseases worldwide.

Further, the market is based on the type of manufacturing; in this segmentation, the in-house manufacturing segment has a major contribution to the peptide therapeutics market share. Most players are involved in the in-house manufacturing process due to strict regulations and high costs incurred in outsourcing. According to the synthesis technology, the liquid phase peptide synthesis (LPPS) segment has dominated the peptide therapeutics market share. The dominance is attributed to the swelling demand for pure peptides in the development of effective therapeutics. Moreover, the liquid phase peptide synthesis holds usefulness in the extensive production of peptides for industrial purposes.

In terms of geographical segmentation, North America has a substantial share of the peptide therapeutics market growth. This is due to the growing demand for diagnostics in cancer, cardiovascular and other diseases, and the expanding biotechnology industry contributes to the dominance. Cancer coupled with cardiovascular diseases is the major cause of death in the developed countries around the world. Traditional cancer treatments lack therapeutic uses because of drug resistance, a dearth of tumor selectivity and solubility, and a requirement to develop new therapeutic agents. Therapeutic peptides are a potential and a new effort to treat various diseases and cancer, which has increased the demand for peptide therapeutics.
The vital players of the peptide therapeutics market are Teva Pharmaceuticals Industries Ltd., Novo Nordisk A/S, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc (GSK), Novartis International AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., and Lonza Inc.

Visit More Information: Click Here